Covered recipient · General Payments record
RONALD G NAHASS
Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$22,696.23
116 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17,600.00 | 7 |
| Food and Beverage | $2,696.45 | 103 |
| Travel and Lodging | $2,364.79 | 5 |
| Education | $34.99 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ViiV Healthcare Company | $15,333.00 | 36 |
| ABBVIE INC. | $5,658.91 | 14 |
| Gilead Sciences, Inc. | $961.88 | 26 |
| Insmed, Inc. | $135.03 | 9 |
| Melinta Therapeutics, LLC | $124.09 | 1 |
| Merck Sharp & Dohme LLC | $113.53 | 7 |
| Ferring Pharmaceuticals Inc. | $64.73 | 4 |
| Theratechnologies Inc. | $60.48 | 4 |
| Janssen Biotech, Inc. | $53.13 | 3 |
| EMD Serono, Inc. | $40.33 | 3 |
| Exact Sciences Corporation | $31.70 | 1 |
| Cumberland Pharmaceuticals, Inc. | $29.69 | 2 |
| Novo Nordisk Inc | $16.68 | 1 |
| AstraZeneca Pharmaceuticals LP | $15.37 | 1 |
| AIMMUNE THERAPEUTICS, INC. | $15.23 | 1 |
| Paratek Pharmaceuticals, Inc. | $14.72 | 1 |
| Tactile Systems Technology Inc | $14.58 | 1 |
| SANOFI PASTEUR INC. | $13.15 | 1 |
Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RONALD G NAHASS
NPI 1023084928 · CMS profile ID 136997
Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease
HILLSBOROUGH, NJ
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1023084928?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RONALD G NAHASS, NPI 1023084928, CMS profile ID 136997. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023084928?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). RONALD G NAHASS, NPI 1023084928, CMS profile ID 136997. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023084928?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- RONALD G NAHASS, NPI 1023084928, CMS profile ID 136997, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 116 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1023084928?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
116 matching records · $22,696.23 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 116.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| EMD Serono, Inc. | $13.16 | 05/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032510255 | CMS |
| Gilead Sciences, Inc. | $109.85 | 05/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025520051 | CMS |
| Gilead Sciences, Inc. | $5.80 | 05/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026118531 | CMS |
| Cumberland Pharmaceuticals, Inc. | $16.41 | 05/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1052122399 | CMS |
| Merck Sharp & Dohme LLC | $15.10 | 05/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048878037 | CMS |
| ViiV Healthcare Company | $3,900.00 | 05/24/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001406831 | CMS |
| Gilead Sciences, Inc. | $17.44 | 05/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025914375 | CMS |
| ViiV Healthcare Company | $25.00 | 05/23/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001406529 | CMS |
| ViiV Healthcare Company | $862.02 | 05/23/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001406667 | CMS |
| ViiV Healthcare Company | $25.00 | 05/23/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001406843 | CMS |
| ViiV Healthcare Company | $120.00 | 05/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001406889 | CMS |
| Gilead Sciences, Inc. | $4.63 | 05/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026135705 | CMS |
| ABBVIE INC. | $15.46 | 05/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997980565 | CMS |
| Gilead Sciences, Inc. | $12.91 | 05/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026047511 | CMS |
| Gilead Sciences, Inc. | $14.84 | 05/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025999367 | CMS |
| ViiV Healthcare Company | $96.88 | 05/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001406083 | CMS |
| ViiV Healthcare Company | $17.59 | 05/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001406009 | CMS |
| Insmed, Inc. | $16.44 | 05/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 978820037 | CMS |
| Insmed, Inc. | $1.57 | 05/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 978820045 | CMS |
| Insmed, Inc. | $12.14 | 05/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 978820047 | CMS |
| Cumberland Pharmaceuticals, Inc. | $13.28 | 05/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1052122393 | CMS |
| Ferring Pharmaceuticals Inc. | $16.13 | 05/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044212243 | CMS |
| ViiV Healthcare Company | $3.22 | 05/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001406541 | CMS |
| EMD Serono, Inc. | $14.44 | 04/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032505763 | CMS |
| ViiV Healthcare Company | $325.00 | 04/21/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001406679 | CMS |
| ABBVIE INC. | $11.31 | 04/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997980563 | CMS |
| Merck Sharp & Dohme LLC | $15.52 | 04/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048485003 | CMS |
| ViiV Healthcare Company | $12.14 | 04/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001406019 | CMS |
| Janssen Biotech, Inc. | $16.77 | 04/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988265655 | CMS |
| ViiV Healthcare Company | $975.00 | 04/12/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001411213 | CMS |
| Gilead Sciences, Inc. | $16.85 | 04/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025933945 | CMS |
| Insmed, Inc. | $6.68 | 04/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 978794357 | CMS |
| ViiV Healthcare Company | $17.76 | 04/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001406635 | CMS |
| ViiV Healthcare Company | $16.53 | 03/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001405995 | CMS |
| ViiV Healthcare Company | $15.51 | 03/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001406601 | CMS |
| Gilead Sciences, Inc. | $123.38 | 03/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025510935 | CMS |
| Merck Sharp & Dohme LLC | $15.15 | 03/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048791811 | CMS |
| ABBVIE INC. | $2,875.00 | 03/21/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997980561 | CMS |
| ViiV Healthcare Company | $17.92 | 03/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001406577 | CMS |
| Insmed, Inc. | $34.99 | 03/15/2023 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 978809539 | CMS |
| ABBVIE INC. | $9.36 | 03/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997980559 | CMS |
| Tactile Systems Technology Inc | $14.58 | 03/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020846869 | CMS |
| ABBVIE INC. | $713.34 | 03/09/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997980555 | CMS |
| ABBVIE INC. | $120.61 | 03/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997980557 | CMS |
| Gilead Sciences, Inc. | $12.55 | 03/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026053389 | CMS |
| ABBVIE INC. | $9.63 | 03/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997980553 | CMS |
| ViiV Healthcare Company | $18.05 | 03/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001406555 | CMS |
| Gilead Sciences, Inc. | $14.07 | 03/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1026020573 | CMS |
| Insmed, Inc. | $15.55 | 03/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 978809537 | CMS |
| ViiV Healthcare Company | $16.79 | 02/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001405399 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $112,076.16 | 127 |
| PY2024 | Principal investigator | $264,452.83 | 175 |
| PY2023 | Principal investigator | $328,056.72 | 110 |
| PY2022 | Principal investigator | $211,836.24 | 128 |
| PY2021 | Principal investigator | $600,558.93 | 221 |
| PY2020 | Principal investigator | $3,759,385.35 | 231 |
| PY2019 | Principal investigator | $607,804.36 | 216 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
127 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | GlaxoSmithKline, LLC. | $406.00 | 11/19/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192185870 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,737.74 | 11/12/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192185849 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $200.00 | 11/05/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192152935 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $430.00 | 11/03/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192156310 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $539.00 | 11/03/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192188713 |
| Principal investigator 1 | Insmed, Inc. | $4,279.39 | 09/12/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650780 |
| Principal investigator 1 | Insmed, Inc. | $264.16 | 09/10/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650776 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $200.00 | 09/05/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192186784 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $660.00 | 08/01/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192185857 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $400.00 | 08/01/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192185861 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,001.00 | 07/31/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192185877 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $350.00 | 07/31/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192188699 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $23,318.46 | 07/14/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192186757 |
| Principal investigator 1 | Insmed, Inc. | $50.00 | 07/09/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650778 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $990.00 | 06/25/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192185845 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 06/25/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192188704 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $200.00 | 06/19/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192186761 |
| Principal investigator 1 | Insmed, Inc. | $250.00 | 06/04/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650766 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $300.00 | 05/30/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192156356 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $660.00 | 05/30/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192188549 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,078.00 | 05/26/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192099033 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $100.00 | 05/26/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192156318 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,800.00 | 05/23/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244787 |
| Principal investigator 1 | Insmed, Inc. | $264.16 | 05/21/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650764 |
| Principal investigator 1 | Insmed, Inc. | $50.00 | 05/21/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650768 |
| Principal investigator 1 | Insmed, Inc. | $50.00 | 05/21/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650770 |
| Principal investigator 1 | Insmed, Inc. | $264.16 | 05/21/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650772 |
| Principal investigator 1 | Insmed, Inc. | $50.00 | 05/21/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650774 |
| Principal investigator 1 | Janssen Research & Development, LLC | $824.00 | 05/20/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244636 |
| Principal investigator 1 | Janssen Research & Development, LLC | $549.00 | 05/20/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244821 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,342.00 | 05/14/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244838 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $100.00 | 05/13/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192156335 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $330.00 | 05/13/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192186776 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $19,203.03 | 04/28/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192156348 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $140.00 | 04/28/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192185874 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $100.00 | 04/28/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192188554 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,819.00 | 04/17/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244669 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,281.00 | 04/15/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244718 |
| Principal investigator 1 | Janssen Research & Development, LLC | $118.00 | 04/11/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244644 |
| Principal investigator 1 | Janssen Research & Development, LLC | $105.00 | 04/11/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244796 |
| Principal investigator 1 | Janssen Research & Development, LLC | $105.00 | 04/10/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244686 |
| Principal investigator 1 | Janssen Research & Development, LLC | $105.00 | 04/10/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244757 |
| Principal investigator 1 | Janssen Research & Development, LLC | $105.00 | 04/10/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244830 |
| Principal investigator 1 | Janssen Research & Development, LLC | $105.00 | 04/10/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244846 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $100.00 | 04/08/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192185853 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $330.00 | 04/08/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192188558 |
| Principal investigator 1 | Insmed, Inc. | $190.50 | 03/31/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650700 |
| Principal investigator 1 | Insmed, Inc. | $63.50 | 03/31/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650702 |
| Principal investigator 1 | Insmed, Inc. | $190.50 | 03/31/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650704 |
| Principal investigator 1 | Insmed, Inc. | $190.50 | 03/31/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650706 |
| Principal investigator 1 | Insmed, Inc. | $298.45 | 03/31/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650708 |
| Principal investigator 1 | Insmed, Inc. | $63.50 | 03/31/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650710 |
| Principal investigator 1 | Insmed, Inc. | $63.50 | 03/31/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650712 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $100.00 | 03/28/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192156314 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $330.00 | 03/28/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192188542 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $100.00 | 03/26/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192156361 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $330.00 | 03/26/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192156368 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,398.00 | 03/25/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244733 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $330.00 | 03/21/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192156352 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $100.00 | 03/21/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192185865 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $330.00 | 03/21/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192188566 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $100.00 | 03/21/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192188709 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,220.00 | 03/14/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244778 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $100.00 | 03/07/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192156364 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $330.00 | 03/07/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192188570 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $100.00 | 03/06/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192156331 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $100.00 | 03/06/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192156371 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $330.00 | 03/06/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192186765 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $100.00 | 02/24/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192152930 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $100.00 | 02/24/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192152940 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $350.00 | 02/24/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192156327 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $100.00 | 02/24/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192186769 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $330.00 | 02/24/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192186772 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $106.00 | 02/24/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192188562 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $330.00 | 02/24/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192188723 |
| Principal investigator 1 | Insmed, Inc. | $35.56 | 02/21/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650742 |
| Principal investigator 1 | Insmed, Inc. | $41.91 | 02/21/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650744 |
| Principal investigator 1 | Insmed, Inc. | $298.45 | 02/21/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650746 |
| Principal investigator 1 | Insmed, Inc. | $19.05 | 02/21/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650748 |
| Principal investigator 1 | Insmed, Inc. | $19.05 | 02/21/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650750 |
| Principal investigator 1 | Insmed, Inc. | $190.50 | 02/21/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650752 |
| Principal investigator 1 | Insmed, Inc. | $50.00 | 02/21/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650754 |
| Principal investigator 1 | Insmed, Inc. | $264.16 | 02/21/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650756 |
| Principal investigator 1 | Insmed, Inc. | $1,157.86 | 02/21/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650758 |
| Principal investigator 1 | Insmed, Inc. | $208.03 | 02/21/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650760 |
| Principal investigator 1 | Insmed, Inc. | $208.03 | 02/21/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650762 |
| Principal investigator 1 | Janssen Research & Development, LLC | $234.00 | 02/21/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244694 |
| Principal investigator 1 | Janssen Research & Development, LLC | $272.00 | 02/19/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244749 |
| Principal investigator 1 | Janssen Research & Development, LLC | $544.00 | 02/14/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244675 |
| Principal investigator 1 | Insmed, Inc. | $0.44 | 02/11/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650692 |
| Principal investigator 1 | Insmed, Inc. | $6,888.84 | 02/11/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650694 |
| Principal investigator 1 | Insmed, Inc. | $0.46 | 02/11/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650696 |
| Principal investigator 1 | Insmed, Inc. | $0.46 | 02/11/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650698 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $330.00 | 02/10/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192156322 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $100.00 | 02/10/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192156339 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $231.00 | 02/10/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192156343 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $51.00 | 02/10/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192186780 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $330.00 | 02/10/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192188689 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $100.00 | 02/10/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192188719 |
| Principal investigator 1 | Janssen Research & Development, LLC | $395.00 | 02/10/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244660 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,342.00 | 02/10/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244701 |
| Principal investigator 1 | Janssen Research & Development, LLC | $351.00 | 02/10/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244708 |
| Principal investigator 1 | Janssen Research & Development, LLC | $351.00 | 02/05/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244741 |
| Principal investigator 1 | Janssen Research & Development, LLC | $234.00 | 02/05/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244764 |
| Principal investigator 1 | Janssen Research & Development, LLC | $395.00 | 02/05/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244851 |
| Principal investigator 1 | Theratechnologies Inc. | $540.00 | 02/03/2025 | Non-covered Recipient Entity I.D. Care Associates, PA | A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) | No dispute reported | 06/30/2026 | 1249666483 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,478.96 | 01/31/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192188546 |
| Principal investigator 1 | Janssen Research & Development, LLC | $285.00 | 01/29/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244652 |
| Principal investigator 1 | Janssen Research & Development, LLC | $395.00 | 01/29/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244725 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $469.00 | 01/28/2025 | Non-covered Recipient Entity ID CARE INC | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO A | No dispute reported | 06/30/2026 | 1192188695 |
| Principal investigator 1 | Insmed, Inc. | $50.00 | 01/24/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650714 |
| Principal investigator 1 | Insmed, Inc. | $264.16 | 01/24/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650716 |
| Principal investigator 1 | Insmed, Inc. | $50.00 | 01/24/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650718 |
| Principal investigator 1 | Insmed, Inc. | $264.16 | 01/24/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650720 |
| Principal investigator 1 | Insmed, Inc. | $264.16 | 01/24/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650722 |
| Principal investigator 1 | Insmed, Inc. | $264.16 | 01/24/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650724 |
| Principal investigator 1 | Insmed, Inc. | $264.16 | 01/24/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650726 |
| Principal investigator 1 | Insmed, Inc. | $264.16 | 01/24/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650728 |
| Principal investigator 1 | Insmed, Inc. | $264.16 | 01/24/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650730 |
| Principal investigator 1 | Insmed, Inc. | $264.16 | 01/24/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650732 |
| Principal investigator 1 | Insmed, Inc. | $35.56 | 01/24/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650734 |
| Principal investigator 1 | Insmed, Inc. | $41.91 | 01/24/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650736 |
| Principal investigator 1 | Insmed, Inc. | $19.05 | 01/24/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650738 |
| Principal investigator 1 | Insmed, Inc. | $19.05 | 01/24/2025 | Non-covered Recipient Entity ID Care Inc | A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact | No dispute reported | 06/30/2026 | 1189650740 |
| Principal investigator 1 | Janssen Research & Development, LLC | $395.00 | 01/22/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244804 |
| Principal investigator 1 | Janssen Research & Development, LLC | $234.00 | 01/17/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244810 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,380.00 | 01/03/2025 | Non-covered Recipient Entity Id Care Infectious Disease | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years | No dispute reported | 06/30/2026 | 1175244771 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2025 | Amount invested | $0.00 | 1 |
| PY2025 | Value of interest | $51,000.00 | 1 |
| PY2024 | Amount invested | $0.00 | 1 |
| PY2024 | Value of interest | $51,000.00 | 1 |
| PY2023 | Amount invested | $0.00 | 1 |
| PY2023 | Value of interest | $51,000.00 | 1 |
| PY2022 | Amount invested | $0.00 | 1 |
| PY2022 | Value of interest | $50,690.00 | 1 |
| PY2021 | Amount invested | $50,000.00 | 1 |
| PY2021 | Value of interest | $50,000.00 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
5 records · PY2021–2025
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2025 | New Wave Endo-Surgical Corp. | $0.00 | $51,000.00 | Investment in company stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1233746453 |
| PY2024 | New Wave Endo-Surgical Corp. | $0.00 | $51,000.00 | Investment | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1145542158 |
| PY2023 | New Wave Endo-Surgical Corp. | $0.00 | $51,000.00 | Equity investment | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1033813675 |
| PY2022 | New Wave Endo-Surgical Corp. | $0.00 | $50,690.00 | n/a | Physician Covered Recipient | No dispute reported | 06/30/2026 | 907505085 |
| PY2021 | New Wave Endo-Surgical Corp. | $50,000.00 | $50,000.00 | none | Physician Covered Recipient | No dispute reported | 06/30/2026 | 838207971 |